- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03835949
Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer
March 31, 2022 updated by: Tracon Pharmaceuticals Inc.
A Phase 1 Dose-Escalation Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer
This is a multicenter, open label, Phase 1 dose escalation study of TJ004309 in combination with standard dose atezolizumab in patients with advanced or metastatic cancer in patients who are refractory to or intolerant to all available therapy.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- The University of Alabama at Birmingham
-
-
Arizona
-
Scottsdale, Arizona, United States, 85258
- HonorHealth Research Institute
-
-
California
-
Duarte, California, United States, 91010
- City of Hope
-
-
Texas
-
Houston, Texas, United States, 77230
- MD Anderson Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically confirmed advanced or metastatic cancer in patients who are refractory to or intolerant to all available therapy.
- Measurable disease by iRECIST
- Formalin fixed, paraffin-embedded (FFPE) tumor tissue that permits the preparation of 12 unstained slides of tumor sample- Biopsy must be excisional, incisional, or core. Needle aspiration is insufficient.
- Age ≥ 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
- Resolution of all acute adverse events resulting from prior cancer therapies to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade ≤ 1 or baseline (except alopecia or neuropathy)
- Adequate organ function
- Willingness and ability to consent for self to participate in study
- Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
Exclusion Criteria:
- Autoimmune disease requiring treatment within the past twelve months
- Condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days prior to study treatment
- History of or active interstitial lung disease
- Prior T-cell or NK cell therapy
- Current treatment on another therapeutic clinical trial
- Receipt of systemic anticancer therapy, including investigational agents, within 28 days prior to study treatment
- Major surgical procedure or significant traumatic injury within 4 weeks prior to study treatment, and must have fully recovered from any such procedure; and no date of surgery (if applicable) or anticipated need for a major surgical procedure planned within the next 6 months
- Chest radiotherapy ≤ 28 days, wide field radiotherapy ≤ 28 days (defined as > 50% of volume of pelvic bones or equivalent), or limited field radiation for palliation ≤ 14 days prior to study treatment - such patients must have recovered adequately from any side effects of such therapy.
- Hypertension defined as blood pressure (BP) systolic > 150 or diastolic > 90 mm Hg
- Ascites or pericardial effusion that required intervention within 3 months prior to study treatment.
- Brain involvement with cancer, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease, unless the lesion(s) have been radiated or resected, are considered fully treated and inactive, are asymptomatic, and no steroids have been administered for CNS disease over the 7 days prior to study treatment
- Angina, myocardial infarction (MI), symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack TIA), arterial embolism, pulmonary embolism, percutaneous transluminal coronary angioplasty (PTCA), or coronary artery bypass grafting (CABG) within 6 months prior to study treatment
- Thrombolytic use (except to maintain IV catheters) within 10 days prior study treatment
- Known active viral or nonviral hepatitis or cirrhosis, except patients with Hepatitis C infection and undetectable virus following treatment are eligible.
- Any active infection requiring systemic treatment
- History of hemorrhage or hemoptysis (> ½ teaspoon bright red blood) within 3 months prior to study treatment
- Known human immunodeficiency virus (HIV) unless CD4+ T cell count > 350 cells/μL with an undetectable viral load.
- Pregnancy or breastfeeding - Female patients must be surgically sterile (i.e., ≥ 6 weeks following surgical bilateral oophorectomy with or without hysterectomy or tubal ligation) or be postmenopausal for at least one year, or must agree to use effective contraception during the study and for 5 months following last dose of TJ004309. All female patients of reproductive potential must have a negative pregnancy test (serum or urine) within 7 days prior to study treatment. Male patients must be surgically sterile or must agree to use effective contraception during the study and for 5 months following last dose of TJ004309.
- Patients with any severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infections should not be enrolled in the trial. Patients who required IV antibiotics or were treated with antiviral medications within this 4 week period should be discussed with the TRACON prior to enrollment.
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TJ004309 plus Atezolizumab
TJ004309 will be dose escalated in a 3+3 design in combination with atezolizumab.
|
Antibody to CD73
Humanized monoclonal antibody to PD-L1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerate Dose of TJ004309 plus Atezolizumab
Time Frame: Approximately 2-8 months
|
Evaluate safety and tolerability and determine a recommended Phase 2 dose of TJ004309 when combined with standard dose atezolizumab in patients with advanced or metastatic cancer.
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 and coded using MedDRA 14.1.
|
Approximately 2-8 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine Phase 2 dose to TJ004309 as a single agent
Time Frame: Approximately 2-8 months
|
Determine the Phase 2 dose of TJ004309 as a single agent
|
Approximately 2-8 months
|
Trough TJ004309 concentrations
Time Frame: Approximately 2-8 months
|
Trough (pre-dose and post-dose) serum TJ004309 concentrations will be measured when given as a single agent and with atezolizumab
|
Approximately 2-8 months
|
Trough atezolizumab concentrations
Time Frame: Approximately 2-8 months
|
Trough (pre-dose and post-dose) serum atezolizumab concentrations will be measured when given with TJ004309
|
Approximately 2-8 months
|
Determine the Rate of TJ004309 Immunogenicity
Time Frame: Approximately 2-8 months
|
The number of patients who develop immunogenicity to TJ004309 (anti-product antibody development) will be determined.
|
Approximately 2-8 months
|
Determine the Rate of Atezolizumab Immunogenicity
Time Frame: Approximately 2-8 months
|
The number of patients who develop immunogenicity to atezolizumab (anti-product antibody development) will be determined.
|
Approximately 2-8 months
|
Assessment of antitumor activity
Time Frame: Approximately 2-8 months
|
Antitumor activity will be assessed by the response rate by iRECIST and RECIST 1.1
|
Approximately 2-8 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Charles Theuer, MD, PhD, Medical Monitor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 16, 2019
Primary Completion (Anticipated)
June 1, 2022
Study Completion (Anticipated)
June 1, 2022
Study Registration Dates
First Submitted
February 5, 2019
First Submitted That Met QC Criteria
February 7, 2019
First Posted (Actual)
February 11, 2019
Study Record Updates
Last Update Posted (Actual)
April 1, 2022
Last Update Submitted That Met QC Criteria
March 31, 2022
Last Verified
March 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4309ST101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Jazz PharmaceuticalsMerck Sharp & Dohme LLCRecruitingAdvanced Solid Tumor | Metastatic Solid TumorUnited States
-
PharmaEngineNot yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor
Clinical Trials on TJ004309
-
I-Mab Biopharma US LimitedCompletedHead and Neck Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Gastrointestinal Cancer | Ovarian CarcinomaUnited States
-
I-Mab Biopharma US LimitedNo longer availableCancerUnited States
-
TJ Biopharma Co., Ltd.Active, not recruiting